

UNDERSTANDING CHRONIC LYMPHOCYTIC LEUKEMIA

Chronic lymphocytic leukemia, or CLL, is a slow-growing cancer in the blood and bone marrow.¹ It is the most common type of adult leukemia in the U.S.²



= 1,000 PEOPLE

18,960

ESTIMATED NEW CASES OF CLL IN THE U.S. IN 2016³

CLL is generally a disease that affects older adults.³

71


AVERAGE AGE AT DIAGNOSIS³

89%


AS MANY AS
MAY HAVE OTHER MEDICAL
CONDITIONS AT DIAGNOSIS⁴

In people with CLL, the leukemia starts in white blood cells called **lymphocytes**.¹

These CLL cells multiply uncontrollably, eventually crowding out normal cells in the bone marrow and in the bloodstream.¹




Sometimes, genetic changes are present in CLL cells that can make the disease more difficult to treat. Common types of genetic changes associated with poor outcomes in people with CLL include:⁵



Signs and symptoms of CLL vary and may take years to appear.¹

Physicians may recommend a “**watch and wait**” or observational approach until disease progression for some people with CLL who do not show any symptoms.⁹

Symptoms of CLL may be seen in other conditions as well. Only a doctor will be able to tell if the symptoms are related to CLL.⁹




PERSISTENT WEAKNESS
AND TIREDNESS




WEIGHT LOSS



SWOLLEN LYMPH NODES
OR ENLARGED SPLEEN



FEVER




REPEATED INFECTIONS




BLEEDING

CLL is incurable.⁸

Although signs of CLL may disappear for a while after initial treatment, many people require additional treatment due to the return of cancerous cells.⁹




RADIATION




CHEMOTHERAPY



BONE MARROW OR STEM CELL
TRANSPLANT



MONOCLONAL ANTIBODIES



OTHER TARGETED AGENTS

REFERENCES

1. National Cancer Institute. Chronic Lymphocytic Leukemia Treatment (PDQ®). <http://www.cancer.gov/types/leukemia/patient/cll-treatment-pdq>. Accessed July 12, 2016.
2. Byrd J. Introduction to a Series of Reviews on Chronic Lymphocytic leukemia (CLL). *Blood*. June 11, 2015. DOI: 10.1182/blood-2015-06-639161.
3. National Cancer Institute. SEER Cancer Statistics Factsheets: Chronic Lymphocytic Leukemia. <http://seer.cancer.gov/statfacts/html/clyl.html>. Accessed July 12, 2016.
4. Thurmes P, Call T, Slager S, et al. Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. *Leuk Lymphoma*. Jan 2008;49(1):49-56.
5. Döhner H, Stilgenbauer S, Benner A, et al. Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia. *N Engl J Med*. December 8, 2000. DOI: 10.1056/NEJM200012283432602.
6. Puiggros A, Blanco G, Espinet B. Genetic Abnormalities in Chronic Lymphocytic Leukemia: Where We Are and Where We Go. *BioMed Res Int*. 2014. DOI: 10.1155/2014/435983.
7. Strati P, Keating MJ, O'Brian SM, et al. Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion. *Haematologica*. Aug 2014;99(8):1350-5. DOI: 10.3324/haematol.2014.104661.
8. Dighiero G and Hamblin T. Chronic Lymphocytic Leukemia. *The Lancet*. 2008; 371:1017-1029.
9. National Cancer Institute. Chronic Lymphocytic Leukemia Treatment – for health professionals (PDQ®). <http://www.cancer.gov/types/leukemia/hp/ctl-treatment-pdq>. Accessed July 12, 2016.